Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIncanthera Regulatory News (INC.PL)

Share Price Information for Incanthera (INC.PL)

Share Price is delayed by 15 minutes
Get Live Data
1.90    0.00 (0.00%)
Bid:
1.70
Ask:
2.10
Spread: 0.40 (23.529%)
Market Cap: £2.62m
INC.PL Live PriceLast checked at - Aquis Stock Exchange

Intraday Incanthera Share Chart

Initiation of Analyst Research and IGTV Interview

25 Mar 2024 14:30

RNS Number : 2009I
Incanthera PLC
25 March 2024
Β 

Β 

Β 

Β 

Β 25 March 2024

Incanthera plc

("Incanthera" the "Company")

Initiation of Analyst Research

Release of IGTV Coverage on Commercial Update

Incanthera plc (AQSE:INC), the company specially focussed on innovative technologies in dermatology and oncology is pleased to announce, following its release of a commercial update this morning, that initiation of analyst research by Stanford Capital Partners is now available on the company's website via the following link:

https://www.incanthera.com/investors/research-notes/?document=2024Β 

Β 

Additionally, Incanthera has released a TV interview by Chairman, Tim McCarthy, on the commercial update and analyst research, to its website which can be accessed via the following links:

Β 

https://www.incanthera.com/news-media/press-coverage/

Β 

and

Β 

https://bcove.video/3VAhLcu

Β 

For further information please contact:

Β 

Incanthera plc

www.incanthera.com

Β 

Tim McCarthy, Chairman

tim.mccarthy@incanthera.com

Β 

Simon Ward, Chief Executive Officer

simon.ward@incanthera.com

Β 

Suzanne Brocks, Head of Communications

suzanne.brocks@incanthera.com

Β 

Β 

Β 

+44 (0) 7831 675747

Β 

Β 

+44 (0) 7747 625506

Β 

Β 

+44 (0) 7776 234600

Β 

Broker:Β 

Stanford Capital Partners Ltd

Patrick Claridge / Bob Pountney

+44 (0) 20 3650 3650/51

Β 

Β 

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature.

Β 

Β 

Notes to Editors

Β 

About Incanthera plc

Β 

Incanthera is a specialist company focused onΒ innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.

Β 

The Company originated from theΒ Institute of Cancer TherapeuticsΒ ("ICT") at theΒ University ofΒ Bradford. Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit:Β www.incanthera.com

Β 

@incantheraplc

Β 

About Skin + CELL

Β 

Skin + CELL is Incanthera's luxury skincare brand utilising our ground-breaking formulation and delivery expertise, to bring scientifically proven formulations to cosmetics. Skin + CELL's unique formulations, enriched with targeted bioactive B3 (an activated form of niacinamide) are delivered directly into the skin's cells to optimise and protect cellular health, energy and protective capabilities.

Β 

Incanthera's skincare technology harnesses unique delivery pathways through recently patented formulations designed by our in-house experts who have previously formulated skincare for some of the world's leading skincare and pharmaceutical companies. These formulations fortify otherwise depleted physiological pathways to improve the skin's performance, ability to self-repair and to address previously unmet cosmetic conditions in skin health.

Β 

? Skin + CELL's unique formulations, currently enriched with targeted bioactive B3 (an activated form of niacinamide) but anticipating further bioactive ingredient formulations are delivered directly into the skin's cells to optimise cellular health, energy and protective capabilities.

? Independent studies have shown Incanthera's technology is uniquely effective in delivering Bioactive B3 below the dermal barrier, energising the living cells of the skin to maintain natural health and protection against adverse environmental challenges and maintaining even skin tones.

? Skin + CELL's complementary range of products are based on advanced, clinically designed, formulation concentrates which combine leading edge pharmaceutical enhancement technology with selected prestige cosmetic ingredients to give an effective product which gives a silky emollience in use and leaves the skin visibly radiant, energised and protected.

Skin + CELL's luxury skincare current range extends across face, body, hand, face serum and eye serum, and will also include SPF concentrations and further bioactive derivatives of vitamins in the future.

About Marionnaud

Β 

Marionnaud is the largest luxury perfumery and cosmetics chain in Europe with over 1,220 stores and a 27% market share in France. Marionnaud is managed by the AS Watson Group based in Hong Kong, the world's largest international health and beauty retailer.

Β 

https://www.marionnaud.com

Β 

About A.S. Watson

Β 

The A.S.Β Watson Group is the world's largest international health and beauty retailer, with 16,100 stores in 28 markets, primarily in Asia and Europe.Β A member of CK Hutchison Holdings, A.S. Watson operates the world's largest portfolio of retail formats, retail brands and has the largest geographical presence including a significant online retail presence.

Β 

http://www.aswatson.com/

https://youtu.be/IZ6TolZi4GoΒ 

Β 

Forward looking statement disclaimer

Β 

Certain statements made in this announcement, or links contained therein, are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholder holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
NEXSEFFLIELSEED
12
Date   Source Headline
4th Jun 20267:00 amRNSCorporate Update
31st Mar 20267:00 amRNSCommercial Update
11th Dec 20257:20 amRNSHalf-year Report
17th Nov 20257:00 amRNS-RAquis Showcase Investor Presentation
10th Nov 202511:04 amRNS-RAGM 2025 Presentation Materials
7th Nov 20252:30 pmRNSResult of AGM
6th Nov 20257:00 amRNSAGM 2025 Update
16th Oct 202510:15 amRNS-RProactive Investor Forum Presentation
14th Oct 20257:00 amRNSNotice of AGM
6th Oct 20257:00 amRNS-RInvestor Presentation
30th Sep 20258:15 amRNSFinal Results
11th Aug 20257:00 amRNSSKIN + CELL COMMERCIAL WEBSITE NOW OPEN FOR SALES
6th Aug 20257:00 amRNSSKIN + CELL TO LAUNCH
9th Jul 20257:00 amRNSHolding(s) in Company
30th Jun 20257:00 amRNSSubscription, Directors' Dealing and RPT
18th Jun 20257:00 amRNSNew Findings on Protective Effects of Skin + CELL
2nd Jun 20257:00 amRNSDirect To Customer Agency Agreement Completed
22nd May 20257:00 amRNSCommercial Update
8th Apr 20257:00 amRNSHolding(s) in Company
1st Apr 20257:00 amRNSWarrant Extension, Debt Conversion & Equity Issue
1st Apr 20257:00 amRNSExtension of Warrants in Incanthera to 30 Sep 2025
28th Mar 20257:00 amRNSCommercial Update
25th Mar 20253:08 pmRNSResolution of Allegations of Patent Infringement
18th Dec 20247:00 amRNSHalf-year Report
26th Nov 20247:00 amRNSCommercial Update
29th Oct 20247:00 amRNSFurther re: Commercial Update
17th Oct 20241:05 pmRNSResult of AGM
26th Sep 20247:00 amRNSCommercial Update
25th Sep 20247:00 amRNSNotice of AGM
9th Sep 20247:01 amRNSExtension of Warrants
27th Aug 20247:00 amRNSFinal Results
14th Aug 20247:00 amRNSExercise of Warrants
11th Jul 20247:00 amRNSCommercial Order Update
25th Jun 20244:00 pmRNSHolding(s) in Company
21st Jun 20242:45 pmRNSHolding(s) in Company
21st Jun 20248:00 amRNSCompletion of Subscription
20th Jun 202411:38 amRNSResult of Meeting
10th Jun 20247:00 amRNSAppointment of NED & Promotion to the Apex Segment
6th Jun 20244:20 pmRNSHolding(s) in Company
4th Jun 20247:00 amRNSAQSE Webinar Presentation
3rd Jun 20247:00 amRNSCommercial Update and Subscription
16th May 20248:07 amRNSInvestor Presentation
25th Apr 20247:00 amRNSHolding(s) in Company
23rd Apr 20242:15 pmRNSFurther re: Exercise of Warrants
17th Apr 20247:00 amRNSFurther re: Exercise of Warrants
9th Apr 20243:00 pmRNSExercise of Warrants
25th Mar 20242:30 pmRNSInitiation of Analyst Research and IGTV Interview
25th Mar 20247:00 amRNSCommercial Update
22nd Feb 20247:00 amRNSGrant of Options
11th Jan 20247:00 amRNSHolding(s) in Company
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.